How iX Biopharma turned conviction into opportunity
AI Summary
Singapore pharmaceutical company iX Biopharma advanced its lead drug program despite losing a key licensing partner, unlocking new commercial opportunities beyond the laboratory. The move highlights resilience in biotech innovation.
After losing a key licensing partner, the Singapore pharmaceutical company continued advancing its lead drug programme. That persistence opened new pathways to commercialisation – and unlocked value beyond the laboratory.